dc.contributor.author | König, Marton | |
dc.contributor.author | Lorentzen, Åslaug Rudjord | |
dc.contributor.author | Torgauten, Hilde Marie | |
dc.contributor.author | Tran, Trung | |
dc.contributor.author | Schikora-Rustad, Stine | |
dc.contributor.author | Vaage, Eline Benno | |
dc.contributor.author | Mygland, Åse Daasvand | |
dc.contributor.author | Wergeland, Stig | |
dc.contributor.author | Aarseth, Jan Harald | |
dc.contributor.author | Aaberge, Ingeborg Sundsvalen | |
dc.contributor.author | Torkildsen, Øivind | |
dc.contributor.author | Holmøy, Trygve | |
dc.contributor.author | Berge, Tone | |
dc.contributor.author | Myhr, Kjell-Morten | |
dc.contributor.author | Harbo, Hanne-Cathrin Flinstad | |
dc.contributor.author | Andersen, Jan Terje | |
dc.contributor.author | Munthe, Ludvig Andre | |
dc.contributor.author | Søraas, Arne Vasli | |
dc.contributor.author | Celius, Elisabeth Gulowsen | |
dc.contributor.author | Vaage, John T. | |
dc.contributor.author | Lund-Johansen, Fridtjof | |
dc.contributor.author | Nygaard, Gro Owren | |
dc.date.accessioned | 2022-06-28T08:32:23Z | |
dc.date.available | 2022-06-28T08:32:23Z | |
dc.date.created | 2021-12-13T13:05:46Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Journal of Neurology, Neurosurgery and Psychiatry. 2021, . | en_US |
dc.identifier.issn | 0022-3050 | |
dc.identifier.uri | https://hdl.handle.net/11250/3001235 | |
dc.description.abstract | Introduction The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development of protective immunity is of paramount importance to fight the COVID-19 pandemic. Objective To characterise humoral immunity after mRNA-COVID-19 vaccination of people with multiple sclerosis (pwMS). Methods All pwMS in Norway fully vaccinated against SARS-CoV-2 were invited to a national screening study. Humoral immunity was assessed by measuring antiSARS-CoV-2 SPIKE RBD IgG response 3–12 weeks after full vaccination, and compared with healthy subjects. Results 528 pwMS and 627 healthy subjects were included. Reduced humoral immunity (anti-SARS-CoV-2 IgG | en_US |
dc.language.iso | eng | en_US |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.title | Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: The relevance of time since last rituximab infusion and first experience from sporadic revaccinations | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.doi | 10.1136/jnnp-2021-327612 | |
dc.identifier.cristin | 1967772 | |
dc.source.journal | Journal of Neurology, Neurosurgery and Psychiatry | en_US |
dc.source.pagenumber | 4 | en_US |